By pushing for price reductions for both second-line and paediatric antiretroviral medicines, UNITAID is helping expand AIDS treatment so that far more adults and children can be treated with the same funds. Additionally, UNITAID's work to develop better and more child-friendly AIDS medicines has helped increase the number of children receiving antiretroviral therapy adapted to their needs.
The best treatment for malaria today, artemisinin-based combination therapy (ACT), is still not reaching enough patients due to the widespread availability of cheaper, but less effective, anti-malarials in developing countries. UNITAID is partnering with the Global Fund to fight AIDS, Tuberculosis and Malaria (GFATM) to regulate the market in low- and middle-income countries by increasing the supply of ACTs and bringing the price down to affordable levels.
TB and its resistant forms, such as multi drug-resistant tuberculosis (MDR-TB), remains very difficult to diagnose and treat. This is due primarily to the fact that there is limited research and development for a disease that is largely considered a part of history in wealthy countries. UNITAID is working to improve and help expand access to MDR-TB treatment. It is supporting better diagnostic methods, in order to detect more patients who can then be treated, and funding the expensive MDR-TB treatment itself. At the same time, by expanding treatment coverage, UNITAID is working to improve the quality of MDR-TB medicines and drive prices down. This, in turn, should help facilitate treatment expansion even further.